Gilead Sciences, Inc. $GILD Shares Bought by Krilogy Financial LLC

Krilogy Financial LLC grew its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 108.6% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 9,608 shares of the biopharmaceutical company’s stock after purchasing an additional 5,001 shares during the period. Krilogy Financial LLC’s holdings in Gilead Sciences were worth $1,331,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Investment Advisory Services Inc. TX ADV purchased a new position in shares of Gilead Sciences during the 1st quarter valued at approximately $234,000. Signal Advisors Wealth LLC purchased a new stake in Gilead Sciences during the first quarter worth $340,000. Anchyra Partners LLC grew its position in Gilead Sciences by 9.9% during the first quarter. Anchyra Partners LLC now owns 3,242 shares of the biopharmaceutical company’s stock valued at $452,000 after buying an additional 293 shares during the period. Summit Wealth Partners LLC acquired a new stake in Gilead Sciences during the first quarter valued at $402,000. Finally, Webster Bank N. A. increased its holdings in Gilead Sciences by 35.5% in the first quarter. Webster Bank N. A. now owns 1,186 shares of the biopharmaceutical company’s stock valued at $165,000 after buying an additional 311 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Trending Headlines about Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: The U.S. FDA approved Trodelvy for first-line treatment of metastatic triple-negative breast cancer, expanding the drug’s addressable market and strengthening Gilead’s oncology growth story. U.S. FDA Approves Trodelvy for First-Line Treatment of Metastatic Triple-Negative Breast Cancer
• Positive Sentiment: Merck also received FDA approval for KEYTRUDA combinations that include Trodelvy, which could increase Trodelvy’s use in combination regimens and support broader adoption. FDA Approves KEYTRUDA combinations with Trodelvy
• Positive Sentiment: Gilead also received European Commission approval to expand Trodelvy’s label in metastatic TNBC, further widening the drug’s commercial opportunity outside the U.S. Gilead Wins EC Approval to Expand Trodelvy’s Label in Metastatic TNBC
• Neutral Sentiment: Short-interest data showed no meaningful change, so it does not appear to be a major driver of the stock’s move.
• Negative Sentiment: Despite the Trodelvy approvals, Gilead’s shares still dipped versus the broader market, suggesting investors may be taking profits or focusing on broader market weakness rather than the regulatory upside. Gilead Sciences Dips More Than Broader Market: What You Should Know

Gilead Sciences Stock Down 1.1%

Shares of NASDAQ GILD opened at $123.84 on Friday. The firm has a market cap of $153.76 billion, a price-to-earnings ratio of 16.87 and a beta of 0.31. The company’s 50-day simple moving average is $130.42 and its 200-day simple moving average is $134.33. The company has a quick ratio of 1.77, a current ratio of 1.97 and a debt-to-equity ratio of 0.89. Gilead Sciences, Inc. has a 52-week low of $105.79 and a 52-week high of $157.29.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share for the quarter, topping the consensus estimate of $1.91 by $0.12. The firm had revenue of $6.96 billion during the quarter, compared to the consensus estimate of $6.91 billion. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The company’s revenue for the quarter was up 4.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.81 EPS. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Equities analysts predict that Gilead Sciences, Inc. will post -0.8 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, June 29th. Stockholders of record on Monday, June 15th will be given a $0.82 dividend. This represents a $3.28 annualized dividend and a dividend yield of 2.6%. The ex-dividend date is Monday, June 15th. Gilead Sciences’s dividend payout ratio (DPR) is 44.69%.

Analysts Set New Price Targets

A number of research analysts have weighed in on the stock. Jefferies Financial Group began coverage on shares of Gilead Sciences in a research report on Tuesday, March 10th. They issued a “buy” rating and a $180.00 price objective for the company. Weiss Ratings lowered Gilead Sciences from a “buy (b)” rating to a “buy (b-)” rating in a research note on Thursday, May 28th. Wall Street Zen cut Gilead Sciences from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 9th. Citigroup increased their price target on Gilead Sciences from $156.00 to $165.00 and gave the stock a “buy” rating in a research report on Monday, April 13th. Finally, Leerink Partners dropped their price objective on Gilead Sciences from $148.00 to $146.00 in a report on Friday, May 8th. Twenty-five research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, Gilead Sciences has a consensus rating of “Moderate Buy” and an average target price of $158.41.

Insider Activity

In other news, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $125.40, for a total value of $376,200.00. Following the sale, the chief financial officer directly owned 171,646 shares of the company’s stock, valued at $21,524,408.40. The trade was a 1.72% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 28,000 shares of the business’s stock in a transaction that occurred on Friday, May 15th. The stock was sold at an average price of $131.29, for a total value of $3,676,120.00. Following the sale, the insider owned 125,779 shares of the company’s stock, valued at $16,513,524.91. The trade was a 18.21% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 68,000 shares of company stock worth $8,930,150 over the last quarter. 0.30% of the stock is currently owned by corporate insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.